Deep learning approach for survival prediction for patients with synovial sarcoma

Synovial sarcoma is a rare disease with diverse progression characteristics. We developed a novel deep-learning-based prediction algorithm for survival rates of synovial sarcoma patients. The purpose of this study is to evaluate the performance of the proposed prediction model and demonstrate its clinical usage. The study involved 242 patients who were diagnosed with synovial sarcoma in three institutions between March 2001 and February 2013. The patients were randomly divided into a training set (80%) and a testing set (20%). Fivefold cross validation was performed utilizing the training set. The test set was retained for the final testing. A Cox proportional hazard model, simple neural network, and the proposed survival neural network were all trained utilizing the same training set, and fivefold cross validation was performed. The final testing was performed utilizing the isolated test data to determine the best prediction model. The multivariate Cox proportional hazard regression analysis revealed that size, initial metastasis, and margin were independent prognostic factors. In fivefold cross validation, the median value of the receiver-operating characteristic curve (area under the curve) was 0.87 in the survival neural network, which is significantly higher compared to the area under the curve of 0.792 for the simple neural network (p = 0.043). In the final test, survival neural network model showed the better performance (area under the curve: 0.814) compared to the Cox proportional hazard model (area under the curve: 0.629; p = 0.0001). The survival neural network model predicted survival of synovial sarcoma patients more accurately compared to Cox proportional hazard model.

[1]  S. Ferrari,et al.  Synovial sarcoma: A retrospective analyis of 250 patients treated in a single institution , 2008 .

[2]  M. Ladanyi,et al.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. , 2002, Cancer research.

[3]  F. Collin,et al.  Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[5]  C. Poremba,et al.  The prognostic impact of SYT‐SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials , 2017, Pediatric blood & cancer.

[6]  F. Collin,et al.  Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[8]  A. Paulino Synovial Sarcoma Prognostic Factors and Patterns of Failure , 2004, American journal of clinical oncology.

[9]  Chin-Shang Li,et al.  Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis , 2014, Journal of surgical oncology.

[10]  P. Lander,et al.  Synovial sarcoma: clinicopathologic features, treatment, and prognosis. , 2007, Orthopedics.

[11]  W. Sirichativapee,et al.  Prognostic factors and clinical outcomes in synovial sarcoma of the extremities , 2013, Asia-Pacific journal of clinical oncology.

[12]  M. Stevens,et al.  Synovial sarcoma in childhood and adolescence: A retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006 , 2010, Pediatric blood & cancer.

[13]  J. Fletcher,et al.  Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Blay,et al.  Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.